Abstract
Advances in understanding of pathogenic cell types and cytokines in Castleman disease have allowed the development of targeted therapies successful in the treatment of both Castleman disease and associated autoimmune disease.
Original language | English (US) |
---|---|
Pages (from-to) | 76-83 |
Number of pages | 8 |
Journal | Current Opinion in Rheumatology |
Volume | 24 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2012 |
Keywords
- B-lymphocyte
- Castleman disease
- Innate immunity
- Interferon
- Interleukin-6
- Plasmacytoid dendritic cell